Welcome to CDC stacks | Assessing adherence to antiretroviral therapy in a rural paediatric cohort in KwaZulu-Natal, South Africa - 42208 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Assessing adherence to antiretroviral therapy in a rural paediatric cohort in KwaZulu-Natal, South Africa
  • Published Date:
    Nov 2016
  • Source:
    AIDS Behav. 20(11):2729-2738.
Filetype[PDF-681.87 KB]


Details:
  • Pubmed ID:
    27289369
  • Pubmed Central ID:
    PMC5071125
  • Description:
    Achieving optimal adherence to ARV's in a rural paediatric population is challenging. Monitoring adherence by frequent viral load assay is not always feasible or sustainable in rural communities. A relatively cheaper, reliable, valid and sustainable measure of adherence for children is required for routine management. This study retrospectively assessed adherence outcomes using monthly pill count and viral load data, including reasons reported for non-adherence, in a paediatric cohort in rural KwaZulu-Natal, South Africa. Between 2008 and 2013, 78 children, mean age of 7.1 years, were enrolled in the CAPRISA 052 AIDS Treatment Programme. Monthly treatment adherence by pill count was categorized as either high (≥95 %) or low (<95 %). Overall median monthly adherence to treatment by pill count was 87.8 % at month 6, 88.9 % at month 12 and 90.8 % at month 24. However, the proportion of children with an undetectable viral load (<400 copies/ml) was 84.0 % (63/74), 86.6 % (58/67), and 84.5 % (49/58) at the three time points respectively. Agreement between pill count and viral load showed that only 33.9, 36. 3 and 30.6 % of children were truly adherent by pill count at months 6, 12 and 24 respectively. In conclusion, this treatment programme demonstrated that adherence of >95 % by pill count is not an ideal indicator of virological suppression in children aged 6 months to 13 years. Viral load assessment remains the gold standard for assessing treatment success in this age group.

  • Document Type:
  • Collection(s):
  • Funding:
    D43 TW000231/TW/FIC NIH HHS/United States
    U01 AI069469/AI/NIAID NIH HHS/United States
    U19 AI051794/AI/NIAID NIH HHS/United States
    U2G PS001350/PS/NCHHSTP CDC HHS/United States
No Related Documents.
You May Also Like: